share_log

EF Hutton Maintains Buy on Lantern Pharma, Maintains $11 Price Target

Benzinga Real-time News ·  Feb 16, 2023 00:05

EF Hutton analyst Michael King maintains Lantern Pharma (NASDAQ:LTRN) with a Buy and maintains $11 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment